1. Home
  2. WNEB vs CRVS Comparison

WNEB vs CRVS Comparison

Compare WNEB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.55

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$11.97

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
CRVS
Founded
1853
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
1.2B
IPO Year
2001
2016

Fundamental Metrics

Financial Performance
Metric
WNEB
CRVS
Price
$13.55
$11.97
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$13.67
$30.17
AVG Volume (30 Days)
31.9K
1.5M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
2.00%
N/A
EPS Growth
33.93
48.04
EPS
0.24
N/A
Revenue
$44,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.25
N/A
P/E Ratio
$56.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.53
$3.55
52 Week High
$14.52
$26.95

Technical Indicators

Market Signals
Indicator
WNEB
CRVS
Relative Strength Index (RSI) 51.55 43.20
Support Level $12.86 $11.42
Resistance Level $14.22 $14.00
Average True Range (ATR) 0.48 0.67
MACD 0.06 0.11
Stochastic Oscillator 77.61 35.96

Price Performance

Historical Comparison
WNEB
CRVS

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: